Sherman, Eric Jeffrey

Publications

Sort by

Co-Author Network

selected publications

Nasopharynx cancer: Induction or adjuvant? That is the question. Cancer. 2020 Editorial Article GET IT
Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Thyroid : official journal of the American Thyroid Association. 2020 Academic Article GET IT
Times cited: 15
Pan-Cancer Efficacy of Vemurafenib in BRAF ^V600-Mutant Non-Melanoma Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 97
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. The Journal of clinical endocrinology and metabolism. 2019 Academic Article GET IT
Times cited: 175
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 156
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 32
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017 Academic Article GET IT
Times cited: 60
Proton therapy for head and neck cancer: expanding the therapeutic window. The Lancet. Oncology. 2017 Information Resource GET IT
Times cited: 54
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer. 2017 Academic Article GET IT
Times cited: 70
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Academic Article GET IT
Times cited: 80
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA oncology. 2017 Academic Article GET IT
Times cited: 186
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. Cancer. 2016 Academic Article GET IT
Times cited: 8
The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. Cancer. 2016 Academic Article GET IT
Times cited: 20
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. International journal of radiation oncology, biology, physics. 2016 Academic Article GET IT
Times cited: 36
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 300
Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. The Laryngoscope. 2016 Academic Article GET IT
Times cited: 7
Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. International journal of radiation oncology, biology, physics. 2016 Academic Article GET IT
Times cited: 125
Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016 Academic Article GET IT
Times cited: 28
Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. American journal of clinical oncology. 2016 Academic Article GET IT
Times cited: 49
Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience. The Laryngoscope. 2015 Academic Article GET IT
Times cited: 16
Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral oncology. 2015 Academic Article GET IT
Times cited: 70
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head & neck. 2015 Academic Article GET IT
Times cited: 31
Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. Oral oncology. 2015 Academic Article GET IT
Times cited: 28
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 7
Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. Cancer. 2015 Academic Article GET IT
Times cited: 56
Reply to D. Adkins et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Article GET IT
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 669
Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. Head & neck. 2014 Academic Article GET IT
Times cited: 7
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral oncology. 2014 Academic Article GET IT
Times cited: 50
Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. Oral oncology. 2014 Academic Article GET IT
Times cited: 18
The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. Oral oncology. 2014 Academic Article GET IT
Times cited: 33
A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014 Academic Article GET IT
Times cited: 69
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of surgical oncology. 2014 Academic Article GET IT
Times cited: 33
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer. Investigational new drugs. 2014 Academic Article GET IT
Times cited: 4
A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. International journal of radiation oncology, biology, physics. 2013 Academic Article GET IT
Times cited: 47
Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. 2013 Academic Article GET IT
Times cited: 61
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 663
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 2013 Academic Article GET IT
Times cited: 40
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Science translational medicine. 2013 Academic Article GET IT
Times cited: 61
Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Article GET IT
Times cited: 12
Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know. Head & neck. 2012 Academic Article GET IT
Times cited: 50
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Academic Article GET IT
Times cited: 37
The role of external beam radiation and targeted therapy in thyroid cancer. Seminars in radiation oncology. 2012 Information Resource GET IT
Times cited: 25
Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. Cancer. 2012 Academic Article GET IT
Times cited: 62
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer chemotherapy and pharmacology. 2012 Academic Article GET IT
Times cited: 27
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 2012 Academic Article GET IT
Times cited: 57
TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. The Laryngoscope. 2012 Academic Article GET IT
Times cited: 22
Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. International journal of radiation oncology, biology, physics. 2011 Academic Article GET IT
Times cited: 42
Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011 Academic Article GET IT
Times cited: 62
A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 34
Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy. Academic radiology. 2011 Academic Article GET IT
Times cited: 33
Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. International journal of radiation oncology, biology, physics. 2011 Academic Article GET IT
Times cited: 62
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. International journal of radiation oncology, biology, physics. 2011 Academic Article GET IT
Times cited: 120
Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer. Clinical advances in hematology & oncology : H&O. 2011 Information Resource GET IT
Times cited: 9
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. International journal of radiation oncology, biology, physics. 2010 Academic Article GET IT
Times cited: 144
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. The Lancet. Oncology. 2010 Information Resource GET IT
Times cited: 204
Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics. 2010 Academic Article GET IT
Times cited: 111
Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR. American journal of neuroradiology. 2009 Academic Article GET IT
Times cited: 173
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 345
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008 Academic Article GET IT
Times cited: 8
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 572
Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clinical lung cancer. 2008 Academic Article GET IT
Times cited: 24
Transoral robotic surgery: radical tonsillectomy. Archives of otolaryngology--head & neck surgery. 2007 Academic Article GET IT
Times cited: 425
Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 33
Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 8
Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). International journal of radiation oncology, biology, physics. 2005 Academic Article GET IT
Times cited: 30
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. 2005 Academic Article GET IT
Times cited: 53
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head & neck. 2005 Academic Article GET IT
Times cited: 52
Using patients as their own controls for cost evaluation of phase I clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 3
Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment. Head & neck. 2004 Academic Article GET IT
Times cited: 42
Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 59
Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 Academic Article GET IT
Times cited: 63
Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clinical lung cancer. 2002 Academic Article GET IT
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer. 2001 Academic Article GET IT
Times cited: 26

more ...

less ...

Background

education and training

M.D., Columbia University College of Physicians and Surgeons 1993
B.A., University of Pennsylvania 1989

Contact

full name

Eric Jeffrey Sherman

VIVO Weill Cornell Medical College

Eric Jeffrey Sherman Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name